We hereby observed remarkable differences in the number of osteoclasts, again independent of the Col1a1-Krm2 genotype, which essentially confirms previous data showing that breast cancer cells activate osteoclastogenesis to ultimately cause osteolytic lesions [8]. This evidence concerns the gene KREMEN2 and breast carcinoma.